Two Sigma Advisers’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-605,510
| Closed | -$51.5M | – | 2692 |
|
|
2020
Q3 | $51.5M | Buy |
605,510
+339,800
| +128% | +$17.2M | 0.15% | 148 |
|
|
2020
Q2 | $9.42M | Buy |
+265,710
| New | +$7.77M | 0.03% | 578 |
|
|
2019
Q4 | – | Sell |
-13,900
| Closed | -$184K | – | 2523 |
|
|
2019
Q3 | $184K | Buy |
13,900
+1,500
| +12% | +$22.1K | ﹤0.01% | 2059 |
|
|
2019
Q2 | $172K | Buy |
+12,400
| New | +$187K | ﹤0.01% | 2157 |
|
|
2018
Q4 | – | Sell |
-70,600
| Closed | -$1.47M | – | 2518 |
|
|
2018
Q3 | $1.47M | Sell |
70,600
-153,300
| -68% | -$3.63M | ﹤0.01% | 1358 |
|
|
2018
Q2 | $5.3M | Sell |
223,900
-103,500
| -32% | -$2.08M | 0.01% | 826 |
|
|
2018
Q1 | $4.78M | Sell |
327,400
-10,600
| -3% | -$173K | 0.01% | 865 |
|
|
2017
Q4 | $5.46M | Buy |
338,000
+2,405
| +0.7% | +$28.4K | 0.01% | 815 |
|
|
2017
Q3 | $4.69M | Buy |
335,595
+204,895
| +157% | +$2.04M | 0.01% | 822 |
|
|
2017
Q2 | $1.15M | Buy |
130,700
+100,500
| +333% | +$706K | ﹤0.01% | 1453 |
|
|
2017
Q1 | $195K | Buy |
30,200
+6,600
| +28% | +$33.4K | ﹤0.01% | 2211 |
|
|
2016
Q4 | $87K | Buy |
+23,600
| New | +$69.8K | ﹤0.01% | 2276 |
|
|
2015
Q1 | – | Sell |
-25,510
| Closed | -$122K | – | 2505 |
|
|
2014
Q4 | $122K | Buy |
+25,510
| New | +$101K | ﹤0.01% | 2304 |
|
Two Sigma Advisers's IMMU Position: Q4 2020 in Review
Two Sigma Advisers sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 605,510 shares — an estimated $51.5M sold.
Two Sigma Advisers first reported a position in IMMU in Q4 2014 and held it in 13 quarters. The position peaked at $51.5M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Two Sigma Advisers reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Two Sigma Advisers sold 605,510 Immunomedics Inc shares in Q4 2020, an estimated $51.5M.
- Two Sigma Advisers first reported a position in Immunomedics Inc in Q4 2014 and held it in 13 quarters.
- Two Sigma Advisers's Immunomedics Inc position peaked at $51.5M in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Two Sigma Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.